Market Performance - The cell immunotherapy sector declined by 1.41%, ranking among the top losers in the concept sector as of the market close on June 26 [1] - Notable declines were observed in companies such as Rongchang Biologics, Yuyuan Pharmaceutical, and Huahai Pharmaceutical, while ST Xiangxue, Shutai Shen, and Tailin Biologics saw gains of 4.19%, 1.71%, and 1.42% respectively [1] Capital Flow - The cell immunotherapy sector experienced a net outflow of 796 million yuan, with 43 stocks facing net outflows, and 5 stocks seeing outflows exceeding 50 million yuan [1] - Rongchang Biologics led the outflow with 110 million yuan, followed by Hengrui Medicine, Huahai Pharmaceutical, and Yuyuan Pharmaceutical with outflows of 104 million yuan, 75 million yuan, and 70 million yuan respectively [1] Top Gainers and Losers - The top gainers in the cell immunotherapy sector included ST Xiangxue, Shutai Shen, and Tailin Biologics, while the largest losers were Rongchang Biologics, Hengrui Medicine, and Huahai Pharmaceutical [1][3] - The trading volume for Rongchang Biologics was notably high, with a turnover rate of 14.96% and a significant drop of 18.36% in stock price [2][3]

Group 1 - The company announced a cash dividend of 0.25 yuan per share (including tax) to all shareholders based on the total share capital after deducting shares held in the repurchase account [1][3] - The company will stop the conversion of its convertible bonds ("华海转债") from July 1, 2025, until the record date for the dividend distribution, with resumption of conversion on the first trading day after the record date [1][3] - The company will adjust the conversion price of the convertible bonds according to the terms outlined in the bond issuance prospectus after the implementation of the profit distribution plan [3] Group 2 - The company held its annual general meeting on May 23, 2025, where the profit distribution plan was approved [1][2] - The company will publish the implementation announcement of the profit distribution and the adjustment of the convertible bond conversion price on July 2, 2025 [3] - Shareholders wishing to enjoy the dividend distribution must convert their bonds by June 30, 2025 [3]

证券代码：600521 证券简称：华海药业 公告编号：临 2025-075 号 转债代码：110076 转债简称：华海转债 浙江华海药业股份有限公司 一、2024 年度权益分派方案的基本情况 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 5 月 23 日召开 2024 年年度股东大会，会议审议通过了《公司 2024 年度利润分配方案》，公司以实施 权益分派股权登记日登记的总股本扣除公司回购专用证券账户股份数后的股本为 基数，向全体股东每股派发现金红利 0.25 元（含税）。公司通过回购专用证券账 户所持有本公司股份不参与本次利润分配。如在实施权益分派股权登记日期前， 因可转债转股、回购股份注销等致使公司总股本发生变动的，公司将维持每股分 配金额不变，相应调整分配总额。 具体内容详见公司分别于 2025 年 4 月 30 日、2025 年 5 月 24 日刊登在中国证 券报、上海证券报、证券时报、证券日报及上海证券交易所网站（www.sse.com.cn） 关于实施 2024 年度权益分派时"华海转债"停止转股 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或 ...

Group 1 - The core viewpoint of the report is the management of the convertible bonds issued by Zhejiang Huahai Pharmaceutical Co., Ltd., including the bond's issuance details, credit ratings, and the use of raised funds [1][2][3][4][5][6][7][8][9] Group 2 - The total amount of the convertible bonds issued is 1,842.60 million yuan, with a term of 6 years and an interest rate that varies from 0.30% in the first year to 1.00% in the third year [1][2] - The funds raised will be allocated to various projects, including 692.60 million yuan for the production of 20 tons of Perindopril and 50 tons of Ramipril, and 600 million yuan for a pharmaceutical and R&D center project [1][6] - The company has maintained a credit rating of AA for both the issuer and the bonds, with a stable outlook [1][2][3] Group 3 - The company reported a 14.91% increase in total revenue for 2024, amounting to 954,742.54 million yuan compared to 830,871.98 million yuan in 2023 [5] - The net profit for 2024 reached 110,746.31 million yuan, reflecting a 35.51% increase from the previous year [5] - The company’s total assets and liabilities remained stable, with total liabilities at 112.41 billion yuan as of December 31, 2024 [7][9] Group 4 - The company has established a mechanism for the management of raised funds, ensuring compliance with the intended use as outlined in the bond issuance documents [6][7] - The company has successfully completed the projects funded by the raised capital, including the production of raw materials and the establishment of a pharmaceutical park [6][7] - The company has reported no significant adverse changes in its operating environment or business continuity [4][6]

浙商证券股份有限公司 关于 浙江华海药业股份有限公司 公开发行可转换公司债券 受托管理事务报告 （2024 年度） | 债券代码 | 债券简称 | | --- | --- | | 110076 | 华海转债 | 债券受托管理人 （注册地址：浙江省杭州市五星路 201 号） 二〇二五年六月 1 | 重要声明 2 | | --- | | 目录 3 | | 第一章 本次债券情况 4 | | 第二章 受托管理人履行职责情况 6 | | 第三章 发行人的经营与财务状况 8 | | 第四章 发行人募集资金使用及专项账户运作情况与核查情况 11 | | 第五章 内外部增信机制、偿债保障措施的有效性分析 17 | | 第六章 债券本息偿付情况以及发行人偿债保障措施的执行情况 18 | | 第七章 发行人在募集说明书中约定的其他义务的执行情况 19 | | 第八章 债券持有人会议的召开情况 20 | | 第九章 发行人偿债意愿和能力分析 21 | | 第十章 可能影响发行人偿债能力的重大事项及受托管理人采取的应对措施 23 | | 第十一章 其他事项 24 | 第一章 本次债券情况 一、可转换公司债券基本情况 重要声明 浙商证 ...

医药生物行业资金流出榜 （原标题：14.41亿元主力资金今日抢筹医药生物板块） 沪指6月23日上涨0.65%，申万所属行业中，今日上涨的有28个，涨幅居前的行业为计算机、国防军工，涨幅分别为2.25%、1.97%。医药生物行业 今日上涨0.89%。跌幅居前的行业为食品饮料、家用电器、钢铁，跌幅分别为0.80%、0.43%、0.11%。 医药生物行业今日上涨0.89%，全天主力资金净流入14.41亿元，该行业所属的个股共475只，今日上涨的有400只，涨停的有6只；下跌的有65只， 跌停的有1只。以资金流向数据进行统计，该行业资金净流入的个股有247只，其中，净流入资金超亿元的有5只，净流入资金居首的是永安药业， 今日净流入资金2.35亿元，紧随其后的是塞力医疗、华海药业，净流入资金分别为1.65亿元、1.25亿元。医药生物行业资金净流出个股中，资金净 流出超3000万元的有9只，净流出资金居前的有众生药业、创新医疗、新诺威，净流出资金分别为1.42亿元、6423.29万元、5901.06万元。（数据 宝） 医药生物行业资金流入榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量 ...

Core Viewpoint - Zhejiang Huahai Pharmaceutical Co., Ltd. has received approval for the registration of Fumaric Acid Quetiapine Sustained-Release Tablets, enhancing its product line in the treatment of mental disorders and increasing market competitiveness [2] Group 1: Product Approvals and Market Potential - The Fumaric Acid Quetiapine Sustained-Release Tablets are developed by AstraZeneca and are primarily used for treating schizophrenia and depressive episodes in bipolar disorder, with a projected domestic market sales of approximately 451 million yuan in 2024 [2] - Huahai Pharmaceutical has recently received multiple drug approvals, indicating strong R&D capabilities and pipeline efficiency, including Dagagliflozin Metformin Sustained-Release Tablets and Tolvaptan Tablets, with projected sales of approximately 195 million yuan and 497 million yuan respectively in 2024 [2] Group 2: Business Growth and Revenue - The formulation business is becoming a growth engine for Huahai Pharmaceutical, with revenue expected to increase from 4.721 billion yuan in 2022 to 5.759 billion yuan in 2024, raising its revenue share from 57.11% to 60.32% [3] - The company has 105 formulation products approved by the US ANDA and 79 products approved by the National Medical Products Administration, covering various therapeutic areas including cardiovascular, mental disorders, and infections [3] Group 3: Strategic Initiatives and Innovations - Huahai Pharmaceutical is committed to advancing its biological innovation drug strategy, with significant investments in R&D for innovative drugs, particularly in oncology and autoimmune diseases [4] - The company’s subsidiary, Shanghai Huatai Biological Pharmaceutical Co., Ltd., is preparing to submit an ANDA for its HB0034 project, aimed at treating generalized pustular psoriasis, with expected approval next year [4]

股票简称：华海药业 股票代码：600521 公告编号：临 2025-072 号 债券简称：华海转债 债券代码：110076 浙江华海药业股份有限公司 关于部分回购股份注销实施暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ? 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 5 月 23 日分别召开第八届董事会第三次会议和 2024 年年度股东大会，会议审议 通过了《关于注销部分回购股份并减少注册资本的议案》，同意公司对回购专用证券 账户中的 10,656,753 股股份予以注销，并相应减少公司注册资本。本次注销完成后， 公 司 总 股 本 将 由 1,507,907,834 股 变 更 为 1,497,251,081 股 ， 公 司 注 册 资 本 将 由 ? 股份注销日：2025 年 6 月 16 日。 一、回购股份情况概述 公司分别于 2021 年 4 月 23 日、2021 年 5 月 18 日召开第七届董事会第二次会 议、2020 年 ...

证券代码：600521 证券简称：华海药业 债券代码：110076 债券简称：华海转债 浙商证券股份有限公司 关于 浙江华海药业股份有限公司 可转换公司债券转股价格调整的 临时受托管理事务报告 债券受托管理人： （浙江省杭州市五星路 201 号） 二〇二五年六月 重要声明 浙商证券股份有限公司（以下简称"浙商证券"）编制本报告的内容及信息 来源于浙江华海药业股份有限公司（以下简称"华海药业"、 "公司"或"发行人"） 对外公布的公开信息披露文件及发行人向浙商证券提供的资料。 浙商证券按照《公司债券发行与交易管理办法》《公司债券受托管理人执业 行为准则》等相关规定及与华海药业签订的《浙江华海药业股份有限公司公开发 行可转换公司债券之受托管理协议》 （以下简称"《受托管理协议》"）的约定编制 本报告。 浙商证券提请投资者及时关注发行人的信息披露文件，并已督促发行人及时 履行信息披露义务。 一、核准文件及核准规模 经中国证券监督管理委员会《关于核准浙江华海药业股份有限公司公开发行 可转换公司债券的批复》（证监许可20202261 号）核准，公司于 2020 年 11 月 2020376 号文同意，公司 184,26 ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2025-072 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 浙江华海药业股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日、2025 年 5 月 23 日分别召开第八届董事会第三次会议和 2024 年年度股东大会，会议审议 通过了《关于注销部分回购股份并减少注册资本的议案》，同意公司对回购专用证券 账户中的 10,656,753 股股份予以注销，并相应减少公司注册资本。本次注销完成后， 公司总股本将由 1,507,907,834 股变更为 1,497,251,081 股，公司注册资本将由 1,507,907,834 元变更为 1,497,251,081 元。 股份注销日：2025 年 6 月 16 日。 一、回购股份情况概述 公司分别于 2021 年 4 月 23 日、2021 年 5 月 18 日召开第七届董事会第二次会 议、2020 年年度股东大会，审议通过《关于以集中竞价交易方式回购公司股份方案 的议案》；2 ...